OA10033A - Solution hypertonique de cisplatine - Google Patents

Solution hypertonique de cisplatine Download PDF

Info

Publication number: OA10033A
Authority: OA; OAPI
Prior art keywords: solution; cisplatin; sodium chloride; chloride; solutions
Prior art date: 1988-11-14

Application number

OA59680A

Other languages

English (en)

French (fr)

Inventor

Murray A Kaplan

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-14

Filing date

1989-11-13

Publication date

1996-10-14

1989-11-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1996-10-14 Publication of OA10033A publication Critical patent/OA10033A/fr

Links

DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 98
229960004316 cisplatin Drugs 0.000 claims abstract description 98
239000000243 solution Substances 0.000 claims abstract description 94
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 17
239000007864 aqueous solution Substances 0.000 claims abstract description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 112
239000011780 sodium chloride Substances 0.000 claims description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
239000002552 dosage form Substances 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 3
239000000945 filler Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 14
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 8
229910052697 platinum Inorganic materials 0.000 abstract description 4
241000894007 species Species 0.000 description 12
210000000988 bone and bone Anatomy 0.000 description 10
238000009472 formulation Methods 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
239000008215 water for injection Substances 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
239000012895 dilution Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000007787 solid Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
PKPZZAVJXDZHDW-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;hydrochloride Chemical compound Cl.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PKPZZAVJXDZHDW-LJTMIZJLSA-N 0.000 description 1
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000005308 flint glass Substances 0.000 description 1
-1 for example Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000076 hypertonic saline solution Substances 0.000 description 1
239000000819 hypertonic solution Substances 0.000 description 1
229940021223 hypertonic solution Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000013638 trimer Substances 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Inorganic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA59680A 1988-11-14 1989-11-13 Solution hypertonique de cisplatine OA10033A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27033088A	1988-11-14	1988-11-14

Publications (1)

Publication Number	Publication Date
OA10033A true OA10033A (en)	1996-10-14

Family

ID=23030884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA59680A OA10033A (en)	1988-11-14	1989-11-13	Solution hypertonique de cisplatine

Country Status (14)

Country	Link
EP (1)	EP0369714A1 (ja)
JP (1)	JPH0321252A (ja)
AU (1)	AU613810B2 (ja)
DD (1)	DD292135A5 (ja)
DK (1)	DK567689A (ja)
FI (1)	FI895340A7 (ja)
HU (1)	HU208074B (ja)
IL (1)	IL92292A0 (ja)
NO (1)	NO894505L (ja)
NZ (1)	NZ231363A (ja)
OA (1)	OA10033A (ja)
PT (1)	PT92300A (ja)
YU (1)	YU216689A (ja)
ZA (1)	ZA898652B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1165455B (it) *	1983-07-06	1987-04-22	Consiglio Nazionale Ricerche	Composizioni polimeriche a base di policaprolattame
JP2006342058A (ja) *	2003-06-20	2006-12-21	Otsuka Pharmaceut Factory Inc	プラスチック製容器入りシスプラチン製剤
DK177529B1 (en) *	2009-10-23	2013-09-08	Bio Bedst Aps	Liposomes with improved storage stability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1119954A (en) *	1978-05-30	1982-03-16	Edmund S. Granatek	Aqueous solution of cisplatin
US4302446A (en) *	1979-10-02	1981-11-24	Bristol-Myers Company	Pharmaceutical compositions
AU541056B2 (en) *	1980-03-31	1984-12-13	Bristol-Myers Company	Pharmaceuticals formulations
IT1153974B (it) *	1982-09-23	1987-01-21	Erba Farmitalia	Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
JPH072645B2 (ja) *	1986-06-12	1995-01-18	日本化薬株式会社	新規白金錯体製剤

1989
- 1989-11-09 FI FI895340A patent/FI895340A7/fi not_active Application Discontinuation
- 1989-11-10 NZ NZ231363A patent/NZ231363A/en unknown
- 1989-11-13 ZA ZA898652A patent/ZA898652B/xx unknown
- 1989-11-13 IL IL92292A patent/IL92292A0/xx not_active IP Right Cessation
- 1989-11-13 OA OA59680A patent/OA10033A/fr unknown
- 1989-11-13 NO NO89894505A patent/NO894505L/no unknown
- 1989-11-13 EP EP89311732A patent/EP0369714A1/en not_active Ceased
- 1989-11-13 PT PT92300A patent/PT92300A/pt not_active Application Discontinuation
- 1989-11-13 DK DK567689A patent/DK567689A/da not_active Application Discontinuation
- 1989-11-13 JP JP1294763A patent/JPH0321252A/ja active Pending
- 1989-11-14 AU AU44683/89A patent/AU613810B2/en not_active Ceased
- 1989-11-14 HU HU895890A patent/HU208074B/hu not_active IP Right Cessation
- 1989-11-14 DD DD89334564A patent/DD292135A5/de not_active IP Right Cessation
- 1989-11-14 YU YU02166/89A patent/YU216689A/xx unknown

Also Published As

Publication number	Publication date
NO894505D0 (no)	1989-11-13
AU613810B2 (en)	1991-08-08
EP0369714A1 (en)	1990-05-23
HU895890D0 (en)	1990-02-28
DD292135A5 (de)	1991-07-25
DK567689D0 (da)	1989-11-13
NZ231363A (en)	1992-03-26
IL92292A0 (en)	1990-07-26
YU216689A (en)	1991-06-30
ZA898652B (en)	1990-07-25
HUT52373A (en)	1990-07-28
AU4468389A (en)	1990-05-17
JPH0321252A (ja)	1991-01-30
PT92300A (pt)	1990-05-31
HU208074B (en)	1993-08-30
DK567689A (da)	1990-05-15
FI895340A7 (fi)	1990-05-15
FI895340A0 (fi)	1989-11-09
NO894505L (no)	1990-05-15

Publication	Publication Date	Title
KR860001503B1 (ko)	1986-09-30	이버멕틴의 수용화 방법
OA10678A (fr)	2002-11-20	Nouvelles formulations liquides stables à base de paracétamol et leur mode de préparation
EP2349217A1 (fr)	2011-08-03	Nouvelle composition à base d'acide gamma-hydroxybutyrique
FR2571966A1 (fr)	1986-04-25	Compositions therapeutiques contenant des anthracyclines-glucosides.
EP1108424A1 (fr)	2001-06-20	Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale
BE1004168A3 (fr)	1992-10-06	Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv.
CN103260616B (zh)	2015-09-09	对乙酰氨基酚的稳定化剂
EP1014948B1 (fr)	2007-06-27	Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
JPWO2008090732A1 (ja)	2010-05-20	医薬組成物
EP1102594B1 (fr)	2002-05-15	Utilisation de chlorure de sodium pour reduire la toxicite gastro-intestinale des derives de la camptothecine
OA10033A (en)	1996-10-14	Solution hypertonique de cisplatine
MC1379A1 (fr)	1982-01-19	Formule pharmaceutique isotonique stabilisee contenant un compose du mercure comme agent de conservation
FR2509174A1 (fr)	1983-01-14	Composition anti-acide a base de n-acetyl-p-aminophenol
EP3373953B1 (fr)	2020-08-26	Composition a action rapide d'insuline comprenant un citrate substitue
BE1004051A4 (fr)	1992-09-15	Solution injectable et procede pour la preparer.
RU2019110218A (ru)	2020-11-13	Новые композиции на основе фуразидина и способы их изготовления
WO1998022107A1 (fr)	1998-05-28	Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
TW202304426A (zh)	2023-02-01	用於注射之包含１－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺的新調配物
EP0830144A1 (fr)	1998-03-25	Compositions pulverulentes et solubles dans l'eau et leurs applications
CH675684A5 (ja)	1990-10-31
WO1992022305A1 (fr)	1992-12-23	Composition therapeutique pour liberation prolongee de magnesium
WO2019008239A1 (fr)	2019-01-10	Iméglimine pour la prévention et/ou le traitement du carcinome hépatocellulaire
JP3430965B2 (ja)	2003-07-28	安定化された脂肪乳剤含有溶液
CA2472124A1 (fr)	2003-07-10	Composes amphiphiles a usage pharmaceutique ou cosmetique
KR20210101193A (ko)	2021-08-18	이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제